Open Orphan PLC Schedule One Update (0696A)
16 Janvier 2020 - 3:00PM
UK Regulatory
TIDMORPH
RNS Number : 0696A
Open Orphan PLC
16 January 2020
Pre-Admission Announcement
Euronext Growth Schedule 1
Announcement to be made by the Applicant prior to admission
in accordance with the Euronext Growth Markets Rule Book
----------------------------------------------------------------------
All Applicants must complete the following
Company name
Open Orphan plc ("Open Orphan" or the
"Company", and together with its subsidiaries
the "Group")
-------------------------------------------------------------------
Company registered address and if different, company trading
address (including postcodes)
Registered Office:
PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair,
London, W1J 8DJ
Trading Offices:
19 Railway Road, Dalkey, Dublin, Ireland
Queen Mary BioEnterprises (QMB) Innovation Centre, 42 New
Road, London, E1 2AX
----------------------------------------------------------------------
Country of incorporation
England and Wales
----------------------------------------------------------------- ---
Company website address containing all information required
by rule 26 (5.26) of the Euronext Growth Markets Rule Books
www.openorphan.com
----------------------------------------------------------------------
Company business (including main country of operation) or,
in the case of an investing company, details of its investing
strategy. If the admission is sought as a result of a reverse
takeover under rule 5.19 of the Euronext Growth Markets
Rule Books, this should be stated
This is a reverse takeover under Rule 14.
Open Orphan is a Clinical Research Organisation that specialises
in rare and orphan drugs. The headquarters are in Dublin,
Ireland and the company also has offices in the UK, France,
the Netherlands and Germany.
Details of securities to be admitted including any restrictions
as to transfer of securities (i.e. where known, number of
shares, nominal value and issue price to which it seeks
admission and the number and type to be held as treasury
shares):
Number of ordinary shares of 0.1 pence each in nominal value
("Ordinary Shares") for which Admission will be sought:
445,622,374
There are no restrictions as to the transferability of the
Ordinary Shares and no Ordinary Shares will be held in treasury.
Capital to be raised on admission (if applicable) and anticipated
market capitalisation on admission:
Expected Market Capitalisation: GBP29.6 million (based on
an enlarged share capital of 445,622,374 and closing price
per Open Orphan Shares of GBP[0.0665] on 15 January 2020)
No capital to be raised on admission
Percentage of Euronext Growth securities not in public hands
on admission
22.8%
---------------------------------------------------------------------------------
Details of any other exchange or trading platform to which
the ex securities (or other securities of the company) are
or will be admitted or traded:
AIM
---------------------------------------------------------------------------------
Full names and functions of directors and proposed directors
(underlining the first name by which each is known or including
any other name by which each is known):
Directors:
Cathal Friel, Executive Chairman
Brendan Buckley, Non-executive Director
Proposed Directors:
Dr Trevor Phillips, Chief Executive Officer
Dr Mark Warne, Non-executive Director
Michael Meade, Non-executive Director
---------------------------------------------------------------------------------
Full names and holdings of significant shareholders, expressed
as a percentage of the issued share capital, before or after
admission (underlining the first name by which each is known
or including any other name by which each is known):
Before Admission:
Name Number of Ordinary Percentage of issued
Shares share capital
Cathal Friel 41,046,981 16.1%
------------------- ---------------------
Anthony (Tony) Richardson 16,313,388 6.4%
------------------- ---------------------
Gresham House Asset Management 13,081,337 5.1%
------------------- ---------------------
Crux Asset Management 11,928,571 4.7%
------------------- ---------------------
Brendan Buckley 7,845,860 3.1%
------------------- ---------------------
After Admission:
Cathal Friel 41,046,981 9.2%
Anthony (Tony) Richardson 16,313,388 3.7%
----------- ------
Gresham House Asset Management 13,081,337 2.9%
----------- ------
Crux Asset Management 11,928,571 2.7%
----------- ------
Brendan Buckley 7,845,860 1.8%
----------- ------
Invesco Ltd 52,485,973 11.8%
----------- ------
Link Fund Solutions Ltd 38,618,608 8.7%
----------- ------
IP Group plc 32,267,791 7.2%
----------- ------
Jupiter Asset Management
Ltd 22,819,579 5.1%
----------- ------
-------------------------------------------------------------------------------------
Names of all persons to be disclosed in accordance with
Chapter 5: Schedule Two, paragraph (h) of the Euronext Growth
Markets Rule Book:
n/a
-------------------------------------------------------------------------------------
i anticipated accounting reference date: 31
December
ii date to which the main financial information
in the admission document has been prepared:
31 December 2019
iii. dates by which it must publish its first
three reports pursuant to Rules 5.14 and 5.15
in the Euronext Growth Markets Rule Book:
31 December 2019 due 30 June 2020, 30 June
2020 due September 2020, 31 December 2020
due 30 June 2021
------------------------------------------------------------------------------- ----
Expected admission date: 20
January 2020
----------------------------------------------------------------------------- ------
Name and address of Euronext
Growth Advisor
Davy Corporate Finance, Davy
House, 49 Dawson Street, Dublin
2, Ireland
Name and address of broker
Arden Partners plc., 125 Old Broad Street, London, EC2N
1AR
-------------------------------------------------------------------------------------
Other than in the case of a Quoted Applicant, details of
where (postal or internet address) the admission document
will be available from, with a statement that this will
contain full details about the Applicant and the admission
of its securities
A copy of the admission document containing full details
about the applicant and the admission of its securities
is available on the Company's website, www.openorphan.com
-------------------------------------------------------------------------------------
Date of notification
16 January 2020
----------------------------------------------------------------------------- ------
New/update: Update
----------------------------------------------------------------------------- ------
This announcement has been issued through the Companies
Announcement Service of Euronext Dublin.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEFLFEVLTIRLII
(END) Dow Jones Newswires
January 16, 2020 09:00 ET (14:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
